These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27258564)

  • 21. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
    Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
    Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IRX1 is a novel gene, overexpressed in high-grade IDH-mutant astrocytomas.
    Sugur HS; Rao S; Sravya P; Athul Menon K; Arivazhagan A; Mehta B; Santosh V
    Pathol Res Pract; 2023 May; 245():154464. PubMed ID: 37116364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
    Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
    Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
    [No Abstract]   [Full Text] [Related]  

  • 28. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
    Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
    Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
    Reis GF; Pekmezci M; Hansen HM; Rice T; Marshall RE; Molinaro AM; Phillips JJ; Vogel H; Wiencke JK; Wrensch MR; Walsh KM; Perry A
    J Neuropathol Exp Neurol; 2015 May; 74(5):442-52. PubMed ID: 25853694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
    Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
    Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
    J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
    Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
    Kickingereder P; Sahm F; Radbruch A; Wick W; Heiland S; Deimling Av; Bendszus M; Wiestler B
    Sci Rep; 2015 Nov; 5():16238. PubMed ID: 26538165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas.
    Ohka F; Shinjo K; Deguchi S; Matsui Y; Okuno Y; Katsushima K; Suzuki M; Kato A; Ogiso N; Yamamichi A; Aoki K; Suzuki H; Sato S; Arul Rayan N; Prabhakar S; Göke J; Shimamura T; Maruyama R; Takahashi S; Suzumura A; Kimura H; Wakabayashi T; Zong H; Natsume A; Kondo Y
    Cancer Res; 2019 Oct; 79(19):4814-4827. PubMed ID: 31431463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.